塞来昔布对头颈部及胃肠道癌症患者癌症恶病质影响的初步研究结果。
Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract.
作者信息
Lai Victor, George Jonathan, Richey Luther, Kim Hong J, Cannon Trinitia, Shores Carol, Couch Marion
机构信息
Doris Duke Clinical Research Fellowship, The Verne S. Caviness General Clinical Research Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
出版信息
Head Neck. 2008 Jan;30(1):67-74. doi: 10.1002/hed.20662.
BACKGROUND
Animal models suggest that cyclooxygenase-2 (COX-2) inhibitors may be beneficial in suppressing cancer cachexia. We investigated the effect of short-course celecoxib on body composition, inflammation, and quality of life (QOL) in patients with cancer cachexia in a phase II clinical pilot trial.
METHODS
Eleven cachectic patients with head and neck or gastrointestinal cancer were randomly assigned to receive placebo or celecoxib for 21 days while awaiting the initiation of cancer therapy. Body composition, resting energy expenditure, QOL, physical function, and inflammatory markers were measured on days 1 and 21.
RESULTS
Patients receiving celecoxib experienced statistically significant increases in weight and body mass index (BMI), while patients receiving placebo experienced weight loss and a decline in BMI. Patients receiving celecoxib also had increases in QOL scores.
CONCLUSIONS
Cachectic patients receiving celecoxib gained weight, experienced increased BMI, and demonstrated improved QOL scores. Compliance was good and no adverse events were seen.
背景
动物模型表明，环氧化酶-2（COX-2）抑制剂可能有助于抑制癌症恶病质。在一项II期临床试点试验中，我们研究了短期使用塞来昔布对癌症恶病质患者身体成分、炎症和生活质量（QOL）的影响。
方法
11例患有头颈部或胃肠道癌症的恶病质患者在等待开始癌症治疗期间被随机分配接受安慰剂或塞来昔布治疗21天。在第1天和第21天测量身体成分、静息能量消耗、生活质量、身体功能和炎症标志物。
结果
接受塞来昔布治疗的患者体重和体重指数（BMI）有统计学意义的显著增加，而接受安慰剂治疗的患者体重减轻且BMI下降。接受塞来昔布治疗的患者生活质量评分也有所提高。
结论
接受塞来昔布治疗的恶病质患者体重增加，BMI升高，生活质量评分改善。依从性良好，未观察到不良事件。
Zotero 插件